Rationale and design of a randomized trial of the dapagliflozin evaluation on atrial fibrillation patients followed Cox-Maze IV: the DETAIL-CMIV study
Open Access
- 2 November 2023
- journal article
- research article
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 25 (11)
Abstract
Dapagliflozin has been widely used for the treatment of type 2 diabetes mellitus (T2DM) and heart failure (HF). However, data concerning the association between dapagliflozin and the recurrence of atrial fibrillation (AF), especially in patients following Cox-Maze IV (CMIV), are rare. We aim to explore the effect of dapagliflozin on the recurrence of AF after CMIV with and without T2DM or HF. The study of dapagliflozin evaluation in AF patients followed by CMIV (DETAIL-CMIV) is a prospective, double-blind, randomized, placebo-controlled trial. A total of 240 AF patients who have received the CMIV procedure will be randomized into the dapagliflozin group (10 mg/day, n = 120) and the placebo group (10 mg/day, n = 120) and treated for 3 months. The primary endpoint is any documented atrial tachyarrhythmia (AF, atrial flutter or atrial tachycardia) lasting 30 s following a blanking period of 3 months after CMIV. DETAIL-CMIV will determine whether the sodium-glucose cotransporter-2 inhibitor dapagliflozin, added to guideline-recommended post-operative AF therapies, safely reduces the recurrence rate of AF in patients with and without T2DM or HF.Keywords
This publication has 28 references indexed in Scilit:
- The Cox-maze IV procedure in its second decade: still the gold standard?European Journal of Cardio-Thoracic Surgery, 2018
- The effect of dapagliflozin treatment on epicardial adipose tissue volumeCardiovascular Diabetology, 2018
- Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na+/H+ exchanger, lowering of cytosolic Na+ and vasodilationDiabetologia, 2017
- Dapagliflozin is associated with lower risk of cardiovascular events and all‐cause mortality in people with type 2 diabetes ( CVD‐REAL Nordic ) when compared with dipeptidyl peptidase‐4 inhibitor therapy: A multinational observational studyDiabetes, Obesity and Metabolism, 2017
- Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysisThe Lancet Diabetes & Endocrinology, 2017
- Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysisThe Lancet Diabetes & Endocrinology, 2016
- 50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort studyThe Lancet, 2015
- 2012 HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation: Recommendations for Patient Selection, Procedural Techniques, Patient Management and Follow-up, Definitions, Endpoints, and Research Trial DesignHeart Rhythm, 2012
- Surgery for atrial fibrillation: recent progress and future perspectiveGeneral Thoracic and Cardiovascular Surgery, 2012
- Electrophysiologic basis, surgical development, and clinical results of the maze procedure for atrial flutter and atrial fibrillation.1995